CDC Website CDC Website

To Join the NPIN community or

Home » Martin Delaney Collaboratory For Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed) » Martin Delaney Collaboratory for Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed)

Due to the evolving COVID-19 situation, NPIN may not have the most up-to-date organization changes to services or hours. Please call the organization or visit their website to find out about any changes. This site does not have information about where to get tested for COVID-19. For COVID-19 information please visit: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html

Debido a la rápida evolución de la situación con respecto al COVID-19, NPIN podría no tener la información mas actualizada de los servicios u horas de las organizaciones. Por favor llame o visite la página web de la organización para conocer los cambios. Este sitio no tiene información sobre donde hacerse la prueba del COVID-19. Para información sobre el COVID-19 por favor visite: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html

Martin Delaney Collaboratory for Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed)

Funding Opportunity Announcement (FOA) is soliciting applications to support research on HIV cure in pediatric populations. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. The cure of HIV infection in people living with HIV (PLWH) is one of the highest priorities of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The goal of the Martin Delaney Collaboratory program is to accelerate progress towards developing strategies to achieve either eradication of HIV infection from the body or a sustained viral remission, as defined by sustained viral suppression following cessation of antiretroviral therapy. Funded projects under this FOA will be expected to expand the knowledge base on HIV latency and persistence in pediatric populations, design and evaluate innovative cure strategies, develop and evaluate assays and other modalities to accurately characterize HIV reservoirs and translate findings to the clinical settings. This funding opportunity will target perinatally infected children and adolescents up to 24 years of age with a primary focus on early treated children.

Letter of Intent Date
11/7/20
Application Due Date
12/7/20
Project Start Date
7/1/21
Application Contact
Ann
Devine
Branch Chief, Grants Management Officer/AIDS and CTU Division Coordinator
240-669-2988
adevine@niaid.nih.gov
Technical Contact
Tania
B.
Lombo, Ph.D.
Scientific/Research Contact
tania.lombo@nih.gov
301-761-7612
Fund Duration
The total project period must be 5 years.
Subjects
Audiences

Fund Number: 

346939

Fund ID: 

RFA-AI-20-036

Last modified: 

6/16/20